Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.60 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | DHPS | P49366 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445391 | 1.00 | HDAC1 (0.60) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL30474831 | 0.87 | LMNA (0.63) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL256555 | 0.87 | LMNA (0.63) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL28901904 | 0.84 | HDAC1 (0.47) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL156266 | 0.83 | PTPN2 (0.55) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL30151656 | 0.83 | BCL2L1 (0.59) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL498133 | 0.83 | BCL2L1 (0.59) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL1886145 | 0.82 | HDAC1 (0.80) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL31207822 | 0.82 | HDAC1 (0.57) | HDAC1PTPN2HDAC3HDAC4HDAC7 | |
| SCHEMBL3747465 | 0.82 | HDAC1 (0.57) | HDAC1PTPN2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4680247-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | Insmed Incorporated (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| WO-2024192416-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20230074558-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER HEALTH AG (DE) | 2006-05-18 | — | — | US | disclosed |
| CN-1675204-A | 2-heteroaryl carboxamides | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | CN | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| US-6900216-B2 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1268489-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | Knoll GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001090105-A1 | ISOTHIAZOLES AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001068653-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | KNOLL GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | HDAC1 790/4885PTPN2 28/4885HDAC3 2102/4885 |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | HDAC1 695/4885PTPN2 3295/4885HDAC3 996/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | HDAC1 9/4885PTPN2 2540/4885HDAC3 13/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | HDAC1 937/4885PTPN2 3473/4885HDAC3 458/4885 |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | CHRNA2, CHRNA6, CHRNA5 | HDAC1 941/4885PTPN2 3310/4885HDAC3 1688/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | HDAC1 1538/4885PTPN2 4293/4885HDAC3 683/4885 |
| US-20230074558-A1 | DIMERIC COMPOUNDS AS STING AGONISTS | STING1, CGAS, MAVS | HDAC1 4794/4885PTPN2 2079/4885HDAC3 4688/4885 |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | GPR119, HTR3B, HTR2B | HDAC1 1492/4885PTPN2 359/4885HDAC3 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.